Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BL M07D1

Next Previous
Drug Profile

BL M07D1

Alternative Names: BL-M07D1

Latest Information Update: 24 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Baili Pharmaceutical; SystImmune
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA damage stimulants; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Gastric cancer

Highest Development Phases

  • Phase III HER2 positive breast cancer
  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Gastric cancer

Most Recent Events

  • 05 Jun 2025 Phase-II/III clinical trials in HER2-positive-breast-cancer (Neoadjuvant therapy, Combination therapy, Late-stage disease) in China (IV) (NCT06891833)
  • 15 May 2025 Phase-III clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06957886)
  • 06 May 2025 Sichuan Baili Pharmaceutical plans a phase III trial for HER2-positive breast cancer (Recurrent, Metastatic disease) in China (IV, Infusion) (NCT06957886)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top